ENTITY
Mabpharm

Mabpharm (2181 HK)

23
Analysis
Industrials • Hong Kong
Mabpharm is a biopharmaceutical company specializing in the research, development, and manufacturing of monoclonal antibody drugs and biosimilars for cancer and autoimmune diseases. Its core products include CMAB009 Enlito, CMAB007 AomaiShu, and CMAB008 Leiting, which treat various conditions such as colorectal cancer, asthma, and rheumatoid arthritis. The company was founded in 2009 and is headquartered in Taizhou, Jiangsu, PRC.
more
•28 Jun 2026 08:30

APAC Healthcare Weekly (June 28) – Insilico, Abbisko, Nippon Shinyaku, Otsuka, Yuhan Corp, Medytox

Few Chinese companies signed outlicensing deals. Nippon Shinyaku’s partner Regenxbio will resubmit gene therapy drug candidate to FDA. Otsuka...

Logo
144 Views
Share
•14 Jun 2026 08:30

APAC Healthcare Weekly (June 14) – Wuxi AppTec, Remegen, CSPC Pharma, Takeda, SK Bioscience Alteogen

US DoD designated Wuxi AppTec as a “Chinese military company.” Takeda’s zasocitinib tops BMS’ Sotyktu in head-to-head trial. Alteogen secured...

Logo
132 Views
Share
•22 Mar 2026 08:30

APAC Healthcare Weekly (March 22) – Hengrui, Microport Neuro, Celltrion, Samsung Bio, Sun Pharma

Celltrion signed KRW375B biologics CMO deal with a global pharma company. Samsung Bioepis expands biosimilar collaboration with Sandoz. 40+ Indian...

Logo
358 Views
Share
bearish•Cross Asset Strategy
•28 Jul 2019 13:24

🇨🇳🇭🇰 That Was The Week That Was • China/Hong Kong 22nd-27th July 2019 @Smartkarma

TW3 CHINA/HONG KONG 22-27 JUNEThis TW3 covers China and Hong Kong and is a companion to the North Asian TW3 published earlier today.  The weight of...

Logo
781 Views
Share
•29 May 2026 08:30

LongBio Pharma IPO: Not Enough Prospective Yet to Prevent Investor Allergy

LongBio has launched its HK IPO consisting of 14M H shares at HK$96.06 per share to fund R&D and commercialization of its core product candidate....

Logo
162 Views
Share
x